Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Journal of Biological Chemistry|April 6, 2011
Differential regulation of two palmitoylation sites in the cytoplasmic tail of the beta1-adrenergic receptorDavid M Zuckerman, Stuart W Hicks, Guillaume Charron, et al.
Traffic (Copenhagen, Denmark)|November 23, 2006
Golgin-160 promotes cell surface expression of the beta-1 adrenergic receptorStuart W Hicks, Troy A Horn, J Michael McCaffery, et al.
Cell Reports. Medicine|December 30, 2025
DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activityAdam P Stockmann, Sylvia Vincent, Lauren Herschelman, et al.
Neoplasia (New York, N.Y.)|July 29, 2017
The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma ModelsStuart W Hicks, Katharine C Lai, L Cristina Gavrilescu, et al.
Mabs|January 12, 2016
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugatesKalli C Catcott, Molly A McShea, Carl Uli Bialucha, et al.
Mabs|April 25, 2014
Non-viral adeno-associated virus-based platform for stable expression of antibody combination therapeuticsGwendolyn M Wilmes, Kimberly L Carey, Stuart W Hicks, et al.
Haematologica|February 9, 2019
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia modelsStuart W Hicks, Chiara Tarantelli, Alan Wilhem, et al.
Molecular Cancer Therapeutics|May 5, 2022
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing TumorsJuniper A Scribner, Stuart W Hicks, Kerstin W Sinkevicius, et al.
Pageof 2